Pfizer Aktie News

Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors.

Over the last half-century, dividend stocks have notably outperformed non-payers -- and have done so while being less volatile than the benchmark S&P 500. While some ultra-high-yielding income stocks are more trouble than they're worth, proper vetting by investors can uncover some genuine bargains.

Jim Cramer has built a strong reputation in the industry. He's the Mad Money host who carefully picks growth stocks that have the potential to survive market ups and downs.

These businesses have both steadily increased their payouts. Lowe's is focusing on the lucrative professional contractor market.

Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight loss drugs.

Realty Income has a robust dividend yield and a rock-solid, diversified business. Pfizer has a high cash balance, is rolling out new products, and is well-poised to grow its business while supporting its dividend.

Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite cost-saving initiatives and the Hess acquisition, leading to subdued dividend growth. Dividend increases in January will generally be modest, with select companies like Fastenal, S&P Global, and C...

Dividend stocks have been under pressure in the past few years due to the broader economy's unpredictable swings.